NCT03703063View on ClinicalTrials.gov

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

September 17, 2021

Study Completion Date

September 17, 2022

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Gemcitabine

Administered by intravenous infusion over 30 minutes.

DRUG

nab paclitaxel

Administered by intravenous infusion over 30-40 minutes.

DRUG

Onivyde

Administered by intravenous infusion over 90 minutes.

DRUG

Leucovorin

Administered by intravenous infusion over 30 minutes.

DRUG

5-fu

Administered by intravenous infusion over 46 hours.

Trial Locations (1)

98101

RECRUITING

Virginia mason medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Benaroya Research Institute

OTHER

NCT03703063 - Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter